Stem cell viability is the percentage of cells in a tested sample classified as alive by a particular test at a particular time. A viability result of 90% means that 90 out of every 100 assessed cells met that test’s criteria. In a dye-exclusion test, this usually means their membranes kept the dye out; it does not establish that they can grow or perform their intended function PMC6716531.
A high percentage is not, by itself, proof that a treatment is safe, effective, or approved. In the United States, approval applies to specific products, not to a viability percentage Approved cellular and gene therapy products.

This is general information, not individual medical advice. The US manufacturing references below do not establish the status of a service in Japan. When checking Japan’s regenerative medicine framework, do not treat a plan filing as proof of treatment effectiveness.
How Viability Is Calculated
Viability (%) = cells classified as viable ÷ total cells assessed × 100. The total includes viable and nonviable cells within the population being counted PMC6716531.
| Total cells in the preparation | Measured viability | Estimated viable cells |
|---|---|---|
| 100 million | 90% | 90 million |
| 100 million | 70% | 70 million |
| 100 million | 50% | 50 million |
These are calculations, not patient results or recommended doses. If the sample contains several cell types, an overall viability result does not tell you how many living stem cells it contains unless the measurement identifies that population.
Why the Number Matters
Viability helps a manufacturer assess a batch and calculate its viable-cell content. Dead cells and debris also need consideration when evaluating administration and product quality. Viability is therefore one part of product testing, not a substitute for the other checks PMC7149600.
How Labs Measure Viability
Two common approaches use dye exclusion to assess membrane integrity. They are not the only ways to assess cell viability, so ask which method appears on the report PMC6716531.
Trypan Blue Counting
In the published Strober protocol, the laboratory mixes one part cell suspension with one part 0.4% trypan blue stock and counts within 3–5 minutes. The cells are suspended in PBS or serum-free medium because serum proteins can interfere with the reading. Unstained cells are counted as viable; blue cells are counted as nonviable. These conditions describe that protocol, not every laboratory’s validated procedure PMC6716531.
Flow Cytometry
Flow cytometry can assess dye exclusion electronically, using dyes such as propidium iodide. A published study also describes a flow-cytometric trypan blue assay. The result still depends on the assay and analysis settings; using an instrument does not automatically make a result correct PMC6716531 PMC4075294.
Why Results Can Differ
Dye exclusion is an indirect measure. A cell may retain an intact membrane even when its capacity to grow or function is compromised. Conversely, a cell with membrane damage may recover. Dye timing and subjective interpretation can also affect the count PMC6716531.
NIST divides viability measurement into four steps: sampling, sample preparation, data collection, and data analysis. In one imaging example, the same field of cells analyzed with the same algorithm gave 19% and 70% viability at different focal planes. That illustrates measurement sensitivity, not a biological improvement in the cells or a typical error range for all tests Addressing sources error cell viability measurement process.
To compare two reports, check the cell population, method, sampling time, and processing stage. A before-freezing result and an after-thaw result describe different checkpoints. Neither should be silently substituted for the other.
What Viability Cannot Tell You
| Measurement | What it tells you |
|---|---|
| Total cell count | How many cells are in the counted population, including viable and nonviable cells. |
| Viable cell count | How many cells meet the assay’s viability criteria. |
| Identity and purity | Which cell types are present and their proportions. |
| Potency | The product’s relevant biological activity linked to its intended effect. |
| Sterility testing | A separate assessment for microbial contamination; a high viability result is not a sterility result. |
For mesenchymal stromal cells (MSCs), the ISCT’s 2006 minimal criteria address plastic adherence, expression of markers including CD105, CD73, and CD90, lack of specified blood-cell markers, and differentiation into bone, fat, and cartilage cells in vitro. These are characterization criteria, not evidence that a batch will improve a patient’s symptoms 16923606.
FDA’s potency assurance guidance describes manufacturing design, controls, in-process testing, and potency lot-release assays. Viability alone does not demonstrate the intended biological activity, and a potency assay is not a guarantee of clinical benefit Guidance industry potency assurance cellular and gene therapy products. Product testing also addresses safety and characterization separately from viability PMC7149600.
What Counts as Good Viability
There is no universal percentage that proves a stem cell product is suitable for treatment. The relevant comparison is with the specification for that product, measured by the specified method at the specified stage.
An older FDA-authored regulatory chapter describes a generally used minimum final-product viability specification of 70% for somatic cellular therapies, with supporting data needed to justify a lower specification. This is historical US manufacturing context, not a universal current rule, a Japanese clinic standard, or a threshold proving effectiveness PMC7149600.
A result of 90% is higher than 70% mathematically, but it does not establish that one treatment is better. Compare the product, cell count, method, timepoint, and other quality results before interpreting the difference.
Fresh and Frozen Reports
“Fresh” and “frozen” describe handling, not a viability grade. For a frozen preparation, ask whether the reported number was measured before freezing or after thawing. For a fresh preparation, ask how long before planned use the sample was tested.
Within the treatment process in Japan, these are questions to clarify with the treating team. A storage label alone does not supply the batch’s measured result.
A Worked Report Example
Suppose a report says “100 million total cells; 90% viability,” but gives no test method or sampling time. The arithmetic suggests 90 million viable cells, assuming the sample is representative. It does not establish 90 million viable stem cells, a result immediately before administration, or an appropriate dose.
This is an illustrative report-reading exercise, not a patient case or firsthand treatment experience. Before relying on such a report, ask for the method, cell population, sample timing, and batch identifier.
Questions to Ask About Your Report
- Which batch and cell population does this result describe?
- Which assay was used, and when was the sample tested?
- Was testing before freezing, after thawing, or near administration?
- Does the stated cell number mean total cells or viable cells of the intended type?
- What is this product’s release specification, and did the batch meet it?
- What happens if a batch fails, and which identity, purity, sterility, and potency checks are available?
- Is the proposed intervention an approved treatment for this indication, an experimental intervention in a trial, or a private clinic service? When assessing a clinic in Japan, ask for documentation rather than relying on the percentage.
Need help preparing questions about a viability report? Contact patient support to ask about obtaining the method, timing, and batch documentation from the treating team. Individual medical interpretation belongs with a qualified clinician.
Contact patient support
Bottom Line
Read viability as a percentage tied to a sample, method, and timepoint. Pair it with the total cell count and the product’s other quality results. A high percentage cannot, on its own, tell you whether the proposed treatment is appropriate for you.
Sources
- Strober: Trypan Blue Exclusion Test of Cell Viability. Laboratory protocol and limitations, 2015.
- FDA: Approved Cellular and Gene Therapy Products. US product approval listing.
- Bauer: Stem Cell-based Products in Medicine—FDA Regulatory Considerations. Historical manufacturing and testing discussion; issue date 2004, online record 2007.
- Avelar-Freitas and colleagues: Trypan blue exclusion assay by flow cytometry. Laboratory assay study, 2014.
- NIST: Addressing Sources of Error in the Cell Viability Measurement Process. Measurement workflow and focus example.
- Dominici and colleagues: Minimal criteria for defining multipotent mesenchymal stromal cells. ISCT position statement, 2006.
- FDA: Potency Assurance for Cellular and Gene Therapy Products. Final guidance, November 2026.




